A. G. Denisova

A. G. Denisova

Auto-generated profile, based on publicly available information

A. G. Denisova

Penza Institute for Postgraduate Medicine – a Branch of Russian Medical Academy for Continuing Professional Education

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2023 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
VSV. I. Strukov
V. I. Strukov
MSM. Yu. Sergeeva-Kondrachenko
M. Yu. Sergeeva-Kondrachenko
OVO. P. Vinogradova
O. P. Vinogradova
ADA. G. Denisova
A. G. Denisova
IMI. Ya. Moiseeva
I. Ya. Moiseeva
SBS. S. Burmistrova
S. S. Burmistrova
Relevance. Osteoporosis is a systemic disease of the skeleton, which is characterized by a decrease in bone mass per unit volume and a violation of the microarchitectonics of bone tissue, which leads to an increase in bone fragility and an increased risk of fractures.Target. The problems of comorbidity of osteoporosis and polypharmacy in the treatment of this disease are considered.Materials and methods. On the basis of the Center for Osteoporosis of the Penza Institute for Postgraduate Medical Education, a branch of the Russian Medical Academy of Continuing Postgraduate Education of Russia, we conducted an open, prospective, randomized study of the comorbid status of age-related patients with osteoporosis in order to improve the diagnosis and pathogenetic therapy of the disease. More than 1400 women took part in the study.The results of a study of the comorbid status of age-related patients with osteoporosis are presented. The expediency of antiresorptive therapy in comorbid patients with osteoporosis is discussed.Conclusions. The characteristics of osteoprotectors of a new generation based on the bioactive component of gonadotropic action are given, and the prospects of these agents in the implementation of a personalized approach in the treatment of osteoporosis, taking into account comorbidity and polypharmacy, are evaluated. Particular attention is paid to the problem of osteosarcopenia and its solution with the help of these osteoprotectors.

27 June 2023 in Medical alphabet
Verified
Journal Article
Open access
PDF file
PPP.A. Poluboyarinov*
P.A. Poluboyarinov*
MSM. Yu. Sergeeva-Kondrachenko
M. Yu. Sergeeva-Kondrachenko
OVO. P. Vinogradova
O. P. Vinogradova
ADA. G. Denisova
A. G. Denisova
DVD. V. Vikhrev
D. V. Vikhrev
AFA. V. Fedorov
A. V. Fedorov
Selenium is a vital trace element, a key agent in the functioning of the human antioxidant system. Maintaining its optimal level in the body prevents the development of a wide range of pathologies and disorders in the functioning of the endocrine, cardiovascular, reproductive, nervous and other systems. Deficiency of this microelement is observed in 50% of Russians, reaching 95–100% in some regions. Therefore, the correction of selenium status is an urgent task of public health, in connection with which research is underway on various selenium compounds that differ in efficiency, degree of bioavailability and toxicity. The most appropriate human physiology, well-absorbed, effective and safe form of selenium is the amino acid l-selenocystin (selenocysteine in a reduced state). This is what formed the basis of the Parafarm drug SELENBIO for women, which allows compensating for selenium deficiency in different categories of the population without the risk of intoxication.